1. Complications of long and intermediate term venous catheters in cystic fibrosis patients: A multicenter study 
Teresa L. May, Alex H. Gifford, Thomas Lahiri, Adam Black, Janet Trang, Alexandra G. Cornell, Karyll Gonzalez, Scott Morin, Mark Napier, Christine W. Duarte, Jonathan B. Zuckerman 
Journal of Cystic Fibrosis 
Volume 17, Issue 1, Pages (January 2018)
DOI: /j.jcf
Copyright © 2017 European Cystic Fibrosis Society Terms and Conditions

2. Fig. 1
Study flow diagram.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2017 European Cystic Fibrosis Society Terms and Conditions

3. Fig. 2 Models for PICC complications.
Panel A. Univariate model (pediatric patients, open circles. Adult patients, black circles). Adult values only are shown for two variables (anticoagulation and pulmonary function status) due to insufficient data within categories to perform comparisons in the pediatric cohort. Whiskers denote 95% CI.
Panel B. Multivariate model. Data are combined for pediatric and adult patients. Whiskers denote 95% CI.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2017 European Cystic Fibrosis Society Terms and Conditions

4. Fig. 3
Provider survey. A questionnaire distributed to 6 providers at the three study sites on two occasions (first survey administered 2006, black circles; second survey administered 2011, white circles).
Question 1: How frequently do you systemically anticoagulate a patient with PICC-associated deep venous thrombosis?
Question 2: How frequently do you systemically anticoagulate a patient with TIVAD-associated deep venous thrombosis?
Question 3: If a patient has had previous venous thrombosis, how often is medical prophylaxis used for recurrent thrombosis?
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2017 European Cystic Fibrosis Society Terms and Conditions

5. Fig. 4
Complication-free survival of TIVADs. Product limit survival estimates are shown with number of TIVADs at risk for adult (solid line) and pediatric (dashed line) patients. Hash marks indicate lines censored at the end of the study period. Median complication-free survival was 846days and 1525days for adult and pediatric patients, respectively. Log-rank comparison of survival probability by age group, p=
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2017 European Cystic Fibrosis Society Terms and Conditions

6. Fig. e1 (online supplement) Number of catheters inserted per patient.
Stacked histogram of number of lines placed per patient. Gray bars indicate pediatric patients and black bars indicate adults.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2017 European Cystic Fibrosis Society Terms and Conditions